Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fulu Baoxinping Oral Liquid is a Traditional Chinese Medicine (TCM) product developed by Tonghua Wantong Pharmaceutical for the treatment of cardiovascular conditions. It is specifically indicated for patients with coronary heart disease (CHD) presenting with frequent ventricular premature beats (VPB), particularly those categorized under the TCM pattern of qi and yin deficiency with phlegm and blood stasis. The formulation aims to regulate heart rhythm and improve cardiac function through a multi-component herbal approach. It has undergone Phase 3 clinical evaluation in China to assess its efficacy and safety compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fulu Baoxinping Oral Liquid.